Through engineering MeT5A-BAP1w-/KO cell lines, which phenocopy BAP1-deficient cancers, Barnett et al. also showed that the BAP1 mediated increase in ASS-1 levels conferred greater resistance to ADI-PEG-20 [32]—which may in turn mean that these tumours do not have elevated GCN2 levels. The gene discussed is BAP1; the disease is neoplasm.